ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1501

Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)

Isaac Cheng1, Martin Li2, Ho SO1, Jack Lee2, Chun Kwok Wong2 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2The Chinese University of Hong Kong, Hong Kong, Hong Kong

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Disease Activity, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Psoriatic Arthritis (PsA) is a complex, heterogeneous disease with chronic inflammation. Disease manifestations include the peripheral joint inflammation, dactylitis, enthesitis and skin psoriasis. Chronic inflammation is associated with structural damage, which jeopardize long-term functional ability. Sensitive biomarkers reflecting disease activity in various disease domains are lacking.

The aim of the study was to define the molecular basis of inflammation in different disease domains through comparative profiling of serum proteins

Methods: This is a cross-sectional study in patients with PsA. Clinical assessment of inflammation in the peripheral joint (clinical Disease Activity in Psoriatic Arthritis [cDAPSA] and swollen joint count), dactylitis digit count, skin (Psoriasis Activity and Severity Index [PASI]) and enthesis (Leeds enthesitis index) were performed. Blood samples were collected for biomarker assay including 48 cytokines, chemokines, growth and angiogenic factors using the Bio-Rad Bioplex assay1 (Table 1). Levels of selected serum proteins were compared between different disease activity scores across various domains using adjusted linear regression with least absolute shrinkage and selection operator (LASSO) modeling.

Results: 100 PsA patients were recruited (age: 51±11 years, male: 52 (52%), disease duration: 9.0±3 years). The cohort had moderate disease activity (DAPSA: 24.4±14.6; PASI: 6.0±7.2). 53 (53%) and 11 (11%) patients were using conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) and biologic DMARDs (bDMARDs) respectively. Using LASSO regression analysis, biomarkers correlating with peripheral joint inflammation were IFN-γ, IL6, SCF and MCP1, while MIP-1α and β-NGF were related to dactylitis. Biomarkers correlating with skin severity were IP10, M-CSF and eotaxin, while IL8, M-CSF and CTACK were related to enthesitis. Details of biomarkers independent predicting various disease severity are listed in table 2-3.

Conclusion: Comparative serum protein biomarker profiling represents a viable method for distinguishing active inflammation in the various disease domains which may be a step forward towards personalized medicine.

Supporting image 1

Table 1 – 48 biomarker panel

Supporting image 2

Table 2 – LASSO regression on various disease activity scores across various disease domains

Supporting image 3

Table 3– Biomarker independently correlating with various disease severity scores across various disease domains


Disclosures: I. Cheng, None; M. Li, None; H. SO, None; J. Lee, None; C. Wong, None; L. Tam, AbbVie, Amgen, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Novartis, Pfizer, Sanofi, AstraZeneca.

To cite this abstract in AMA style:

Cheng I, Li M, SO H, Lee J, Wong C, Tam L. Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/comparative-profiling-of-serum-protein-biomarkers-and-disease-activity-across-various-disease-domains-in-patients-with-psoriatic-arthritis-psa/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-profiling-of-serum-protein-biomarkers-and-disease-activity-across-various-disease-domains-in-patients-with-psoriatic-arthritis-psa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology